TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Patients who have Moderate MR documented by color flow doppler:~1. LV ejection fraction \> 55%; LV end-systolic dimension \< 4.0 cm.~2. Quantifiable by Doppler-Echo equal or more than moderate in severity.~3. Organic disease of the mitral valve demonstrated by echocardiography (not normal valve as in functional or ischemic MR).~4. Isolated MR (no valve disease other than mild tricuspid or pulmonic regurgitation by Doppler-Echocardiography that is often associated with mitral valve prolapse).~5. Asymptomatic (or mildly symptomatic but not considered as candidates for immediate surgery by their attending physician).~Exclusion Criteria:~1. Significant obstructive coronary artery disease and/or myocardial ischemia on graded exercise test with myocardial perfusion.~2. Previous myocardial infarction or percutaneous coronary intervention.~3. Hypertrophic cardiomyopathy, congenital or pericardial disease.~4. Aortic valve disease (\> trace aortic regurgitation or mean gradient \> 10 mmHg).~5. Mitral stenosis (mean gradient \>5 mmHg, valve area \< 1.5 cm2).~6. Intolerance or contraindication to Beta1-AR blockade.~7. Renal failure with creatinine \> 2.5 mg/dl.~8. Hypertension requiring medical treatment or renal artery stenosis.~9. Severe comorbidity: liver disease, malignancy, collagen vascular, steroid requirement.~10. Pregnancy (negative pregnancy test and effective contraceptive methods are required prior to enrollment of females of childbearing potential).~11. Uncontrolled (rate \> 120/min) or recent (\<4 weeks) atrial fibrillation.~12. Routine, regular use of anti-inflammatory medications.~Exclusion Criteria Related to MRI~1. Severe claustrophobia.~2. Presence of a pacemaker or non-removable hearing aid.~3. Presence of metal clips in the body.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Toprol XL (Type: ACTIVE_COMPARATOR): beta 1 receptor blockade; generic name metoprolol succinate
- Placebo (Type: PLACEBO_COMPARATOR): Pill that looks like Toprol XL but does not have the active ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CONtrolled Focal Fibrous Band Release Method Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe cellulite~Exclusion Criteria:~* Body Mass Index ≥30.0

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Targeted Verifiable Subcision (TVS) with the Avéli device, mITT (Type: EXPERIMENTAL): Modified intent to treat population (n=68). The modified intent to treat population was used to evaluate effectiveness.~The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks
- Targeted Verifiable Subcision (TVS) with the Avéli device, Roll-in (Type: EXPERIMENTAL): The roll-in population (n=6) was excluded from the effectiveness analyses. For Investigators that have not previously performed an Avéli procedure, two (2) participants were classified as roll-in participants. The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: INtraoperative photoDYnamic Therapy of GliOblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient male or female ≥18 years~2. General status (WHO) of Performance status 0, 1 or 2~3. Probable glioblastoma according to clinical and radiological criteria,~4. whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology,~5. Decision to treat the patient as part of the Clinical trial also taken in neuro-oncology RCP (Multidisciplinary consultation meeting)~6. Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical check-up sufficient to insure a post-operative state with normal daily life~7. Clinical neuro-oncological monitoring and long-term MRI scheduled at the hospital CHRU of Lille, center of reference of the region~8. Patient able to understand and sign voluntarily Informed consent~9. Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol~10. Women of child-bearing potential should benefit of an effective contraception~11. For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5-ALA~12. Patient assigned to an heath insurance~Exclusion Criteria:~1. Contraindications to 5-ALA (Gliolan®) and to per-operative PhotoDynamic Therapy perPDT:~2. Contraindications to 5-ALA~   * Porphyria~  * Taking photosensitizer treatment~  * Severe renal or hepatic impairment~  * Bilirubin\> 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)\> 2.5 x Maximum. rates~  * Creatinine clearance \<30 mL / min;~  * Non-compliance with the rules of prevention of the transient risk of cutaneous photosensitization~3. Contraindications to surgery~4. Contraindications to magnetic resonance imaging (MRI)~5. Treatment with an experimental drug within 30 Days prior to the start of the study~6. Clinical follow-up impossible to perform for psychological, familial, social or geographical reasons,~7. Legal incapacity (persons deprived of their liberty or Guardianship or guardianship),~8. Pregnant or nursing women~9. Refusal to participate or sign the consent of the study~10. Soy allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- perPDT (Type: EXPERIMENTAL): Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Visual Cues and Education for People Who Live Within Long Term Care Communities to Assist in Wayfinding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 62 or older;~* Wayfinding impairment identified by the subject or staff and exhibited at baseline, including problems finding their way among three defined locations (these may differ among care communities);~* Ability to move self either independently by walking or using mobility aids (self-mobile; any mobility aids are acceptable)~* Ability to communicate with researchers and follow directions~* Ability to see and read signs in English.~Exclusion Criteria:~* Chronic health conditions that impair the ability to participate in the study, such as severe chronic obstructive pulmonary disease (COPD) (limiting movement) or terminal illness;~* Signs of rapid deterioration in health during the past 6 months as evidenced by staff communication or medical records.

- Gender: ALL
- Minimum Age: 62 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
- Salient Cues (Type: EXPERIMENTAL): Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
- Spaced retrieval education (Type: EXPERIMENTAL): This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>2 months and \<18 years of age at the time of the Primovist/Eovist enhanced MRI~* MRI with Primovist/Eovist due to suspected or known focal liver lesions~* Evaluable safety data~* Evaluable efficacy data: precontrast and postcontrast magnetic resonance (MR) images must be available for review~* If the above criteria are met, the principal investigator (PI) and/or designee will obtain a signed consent for medical records release including access to anonymized electronic copies of the pre- and post-Primovist/Eovist MRI scans, in accordance with local regulatory requirements in order for subjects to be enrolled in the study.~Exclusion Criteria:~* A subject will be excluded from this observational / retrospective study if the subject has previously been enrolled into this study. Subjects may only be entered once into this study, even if they have been imaged multiple times and for different indications.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* salmon \& Durie stage II/III A or B~* previous lenalidomide refractory disease~* patient commits to pregnancy prevention programme~Exclusion Criteria:~* non-secretory myeloma~* known hypersensitivity to lenalidomide~* inadequate marrow reserve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- lenalidomide, endoxan, prednisone (Type: EXPERIMENTAL): lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Had been taking a sulfonylurea for at least 4 weeks prior to the initiation of the observation period (Week -12).~2. Had been taking glimepiride at a stable dose regimen (1, 2, 3 or 4 mg/day, once or twice daily in the morning or in the morning and evening, before or after meal) for at least 12 weeks prior to the initiation of the treatment period (Week 0).~3. Had glycosylated hemoglobin (HbA1c) of 7.0% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).~4. Had an HbA1c difference between 4 weeks after the initiation of the observation period (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being within 10.0%\* of the value at 4 weeks after the initiation of the observation period (Week -8) (\*rounded off to the first decimal place).~5. Was receiving specific diet and exercise (if any) therapies during the observation period.~Exclusion Criteria:~1. Had taken other diabetic medications than glimepiride within 12 weeks before the initiation of the treatment period (Week 0).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 12.5 mg QD and Glimepiride QD or BID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 25 mg QD and Glimepiride QD or BID (Type: ACTIVE_COMPARATOR): None
- Glimepiride 1, 2, 3 or 4 mg QD or BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Clinical (patients) part~1. Signed informed consent~2. Gender: Male or Female~3. Age: 18-65 years of age~3. Clinically and/or endoscopically confirmed diagnosis of GERD~Exclusion Criteria:~Clinical: (patient)~1. Current treatment with proton pump inhibitors and/or histamine-2 receptor antagonists. These treatments should have been stopped at least 1 week prior to study inclusion.~2. Female patients who are pregnant, planning to become pregnant or lactating~3. Any acute diseases or conditions, exacerbations of concomitant chronic diseases (including but not limited to inflammatory bowel disease (IBD), ulcer disease etc.) at study start/inclusion and/or which are not resolved 14 days prior to study-enrolment.~4. Participation in a clinical trial in the past 3 months~5. Any condition which, in the opinion of investigator, makes the patient unsuitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NERD patients (Type: EXPERIMENTAL): Patients have typical reflux syndrome without esophageal injury.
- EE patients (Type: EXPERIMENTAL): Patients have erosion(s) or ulcer(s) in esophagus.
- BE patients (Type: EXPERIMENTAL): Patients have esophageal specialized intestinal metaplasia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed onychomycosis of the target nail~* Presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected~* Has a positive KOH examination from the target nail~* Has a positive dermatophyte culture from the target nail~Exclusion Criteria:~* Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug~* Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis~* Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit~* Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IDP-108 (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Glutathione Supplementation on the Levels of Blood Glutathione

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and females between the ages of 30 and 79 years of age~* Not taking glutathione as a dietary supplement~* Not taking high dose antioxidant supplement prior to 1 month~* Baseline blood glutathione level of \< 1 mmol/L~Exclusion Criteria:~* History or evidence of disease including cancer, diabetes, heart disease~* Subjects who smoke

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases
- Group B (Type: EXPERIMENTAL): Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases
- Group C (Type: PLACEBO_COMPARATOR): Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female dyspeptic subjects aged ≥18 years with any nationality~* Patients with gastric biopsy-proven H. pylori related chronic gastritis and no other abnormalities in the upper gastrointestinal tract upon endoscopy~* Patients who were naive to treatment for H. pylori infection.~Exclusion Criteria:~* Pregnant or breastfeeding females~* Patients who were previously treated for H. pylori infection~* Patients who received any antibiotics, bismuth or acid-suppressant drugs within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard triple therapy (Type: ACTIVE_COMPARATOR): Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
- Quadruple therapy group (Type: EXPERIMENTAL): Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Airway Responses to Montelukast and Desloratadine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* baseline FEV1 \> or = 65% predicted~* positive methacholine challenge (i.e. methacholine PC20 \< or = 16mg/ml~* positive allergen challenge~Exclusion Criteria:~* negative skin prick test~* lung condition/disease other than asthma~* currently use montelukast and/or desloratadine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indomethacin Decreases Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* If they met one or more of the following criteria:~  * a clinical suspicion of SOD dysfunction;~ * or a history of post-ERCP pancreatitis, pancreatic~ * or precut sphincterotomy,~ * more than eight cannulation attempts,~ * pneumatic dilatation of an intact biliary sphincter,~ * or ampullectomy~* Patients were also eligible for inclusion if they met two of the following criteria:~  * aged 50 years or younger and female gender~ * or a history of recurrent pancreatitis (\>2 episodes),~ * three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas,~ * excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,~ * or the need for acquisition of a cytology specimen from the pancreatic duct with the use of a tissue-sampling brush.~Exclusion Criteria:~* unwillingness or inability to consent for the study~* pregnancy~* breast feeding~* standard contraindications for ERCP~* hypersensitivity to aspirin or NSAIDs~* previous use of NSAIDs within 1 week~* renal failure (creatinine clearance rate \>1.4 mg/dL)~* active or recent (\< 4 weeks) gastrointestinal hemorrhage~* chronic calcified pancreatitis~* pancreatic head malignancy~* any procedure performed on the major papilla/ventral pancreatic duct in patients with a pancreatic divisum~* previous ERCP for biliary stent removal or exchange without an anticipated pancreatogram~* subjects with prior biliary sphincterotomy and scheduled for repeat biliary therapy without an anticipated pancreatogram~* or anticipated inability to follow our protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: EXPERIMENTAL): 100 mg of Indomethacin suppository immediately afterwards while still under sedation
- 2.6-g suppository of glycerin (Type: PLACEBO_COMPARATOR): suppository of 2.4 g of glycerin immediately afterwards while still under sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete